Clinical Trial Update: Effect of Renal Impairment on the Pharmacokinetics of NN9535 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating how renal impairment affects the pharmacokinetics of NN9535 in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NN9535

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED